Home
Login
Help
Search this site:
Registered Trials
By recruitment status
By sponsor
By registration date
Advanced search for trials
Registration process
To register a trial
Sponsor registration form
RPCEC trial registration Data Set
To update a registered trial
To disclosure the results of registered trial
Home
|
By sponsor
CENTER OF MOLECULAR IMMUNOLOGY
Trials shown by sponsor
Public title
Date of Registration
State
99mtc-marked 14f7 MAb in colon/rectum tumor, Phase II
2010-12-17
Registered
NGcGM3/VSSP/Montanide ISA 51 vaccine for breast cancer IIa, IIb and IIIa surgically treated with positive ganglia and disease-free, Phase IIb/III.
2010-12-17
Registered
Use of h-R3 monoclonal antibody and radiotherapy to treat patients with advanced epithelial head and neck tumors.
2010-12-17
Registered
EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors
2013-06-19
Registered
EGF vaccine- Advanced Lung tumors
2013-06-20
Registered
Nimotuzumab in the treatment of patients with acute respiratory difficulty syndrome (ARDS)
03/03/2023
Registered
Vaccine HER1 / VSSP for prostate cancer, head and neck carcinoma and advanced colon cancer . Phase I
03/11/2017
Registered
Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors
17/02/2017
Registered
14F7 in chronic B-cell lymphoproliferative syndrome
07/03/2018
Registered
EC122 HER-1 Prostate Phase I
15/11/2016
Registered
NGcGM3/VSSP in Metastatic melanoma
07/12/2016
Registered
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer.
23/05/2014
Registered
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer
12/10/2016
Registered
hR3 in metastatic or recurrent colorectal cancer
22/11/2013
Registered
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer.
26/05/2014
Registered
CIMAVax EGF in Lung Cancer in PHC. Phase IV
05/08/2014
Registered
Itolizumab for Relapsing Remitting Multiple Sclerosis
22/05/2015
Registered
Predictor of response with CIMAvax EGF© in NSCLC Phase III
29/01/2016
Registered
Itolizumab for Moderate-to-Severe Psoriasis-phase 3
08/10/2015
Registered
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus
23/12/2016
Registered
« first
‹ previous
1
2
3
4
5
next ›
last »
About the RPCEC
Structure and governance
Policy
Publications
Awards
Communications
News
Useful resources
Fundamentals of the registry
References of clinical trials
Cuban regulations
Other registries
International Clinical Trials Registry Platform